No Data
AstraZeneca Hits 4-week Low
Assemblin Caverion Group Unit to Upgrade AstraZeneca's Swedish Plant
AstraZeneca to Set Up Beijing R&D Center for $2.5 Billion
HBM HOLDINGS-B opened nearly 15% higher in the morning after reaching a Global Strategy partnership with AstraZeneca.
HBM HOLDINGS-B (02142) opened nearly 15% higher in the early session, and as of this writing, the stock price has risen by 12.77%, currently at 8.83 HKD, with a trading volume of 96.8291 million HKD. HBM HOLDINGS announced the issuance of 76.2717 million new shares to the Global biopharmaceutical company AstraZeneca at a price of 10.74 HKD per share, reflecting a premium of 37.2% compared to the closing price on March 21, with total proceeds of 0.105 billion USD to be used for research and development, operations, and general working capital needs.
Crisis and Redemption: The Darkest Moment and Dawn of the Vaccine Industry.
The vaccine Industry is currently facing challenges, but its fate is not simply a one-way decline.
Notable Healthcare Headlines for the Week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in Focus
